drugset / Trial / NCT01248949
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.
Timeline
- Start
- 2010-10
- Primary completion
- 2015-07
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | MEDI3617 | Monoclonal antibody | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |